Erech Finance Cahalacha Ltd (EFNC) - Net Assets
Based on the latest financial reports, Erech Finance Cahalacha Ltd (EFNC) has net assets worth ILA4.33 Million ILA (≈ $11.62K USD) as of December 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA23.47 Million ≈ $62.93K USD) and total liabilities (ILA19.14 Million ≈ $51.31K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Erech Finance Cahalacha Ltd balance sheet assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA4.33 Million |
| % of Total Assets | 18.46% |
| Annual Growth Rate | -1.78% |
| 5-Year Change | -63.16% |
| 10-Year Change | N/A |
| Growth Volatility | 335.0 |
Erech Finance Cahalacha Ltd - Net Assets Trend (2014–2023)
This chart illustrates how Erech Finance Cahalacha Ltd's net assets have evolved over time, based on quarterly financial data. Check Erech Finance Cahalacha Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Erech Finance Cahalacha Ltd (2014–2023)
The table below shows the annual net assets of Erech Finance Cahalacha Ltd from 2014 to 2023. For live valuation and market cap data, see how much is Erech Finance Cahalacha Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | ILA4.33 Million ≈ $11.62K |
-84.72% |
| 2022-12-31 | ILA28.37 Million ≈ $76.05K |
-46.64% |
| 2021-12-31 | ILA53.16 Million ≈ $142.52K |
+76.78% |
| 2020-12-31 | ILA30.07 Million ≈ $80.62K |
+155.66% |
| 2019-12-31 | ILA11.76 Million ≈ $31.53K |
-34.40% |
| 2018-12-31 | ILA17.93 Million ≈ $48.07K |
+28560.32% |
| 2017-12-31 | ILA-63.00K ≈ $-168.90 |
+95.74% |
| 2016-12-31 | ILA-1.48 Million ≈ $-3.97K |
-931.46% |
| 2015-12-31 | ILA178.00K ≈ $477.21 |
-96.51% |
| 2014-12-31 | ILA5.09 Million ≈ $13.65K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Erech Finance Cahalacha Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6214600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA1.83 Million | 42.21% |
| Other Comprehensive Income | ILA5.19 Million | 119.69% |
| Other Components | ILA59.46 Million | 1372.35% |
| Total Equity | ILA4.33 Million | 100.00% |
Erech Finance Cahalacha Ltd Competitors by Market Cap
The table below lists competitors of Erech Finance Cahalacha Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Heads UP Ventures Limited
NSE:HEADSUP
|
$1.61 Million |
|
Northern 2 Vct Plc
LSE:NTV
|
$1.61 Million |
|
Midwich Group PLC
LSE:MIDW
|
$1.61 Million |
|
Fimperkasa Utama Tbk PT
JK:FIMP
|
$1.62 Million |
|
Engineer Gold Mines Ltd
V:EAU
|
$1.60 Million |
|
FDM Group Holdings PLC
LSE:FDM
|
$1.60 Million |
|
NO GRAVITY GAMES ZY -10
F:8YX
|
$1.59 Million |
|
ModuLink Inc.
NASDAQ:MDLK
|
$1.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Erech Finance Cahalacha Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 28,850,000 to 4,333,000, a change of -24,517,000 (-85.0%).
- Net loss of 25,293,000 reduced equity.
- Other comprehensive income decreased equity by 1,063,000.
- Other factors increased equity by 1,839,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-25.29 Million | -583.73% |
| Other Comprehensive Income | ILA-1.06 Million | -24.53% |
| Other Changes | ILA1.84 Million | +42.44% |
| Total Change | ILA- | -84.98% |
Book Value vs Market Value Analysis
This analysis compares Erech Finance Cahalacha Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 138.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.16x to 138.36x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | ILA1473.24 | ILA236.30 | x |
| 2015-12-31 | ILA51.49 | ILA236.30 | x |
| 2016-12-31 | ILA-14.80 | ILA236.30 | x |
| 2017-12-31 | ILA-0.62 | ILA236.30 | x |
| 2018-12-31 | ILA15.12 | ILA236.30 | x |
| 2019-12-31 | ILA7.54 | ILA236.30 | x |
| 2020-12-31 | ILA16.71 | ILA236.30 | x |
| 2021-12-31 | ILA24.35 | ILA236.30 | x |
| 2022-12-31 | ILA11.37 | ILA236.30 | x |
| 2023-12-31 | ILA1.71 | ILA236.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Erech Finance Cahalacha Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -583.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8969.15%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 5.42x
- Recent ROE (-583.73%) is above the historical average (-1056.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -929.49% | -8290.54% | 0.04x | 2.72x | ILA-47.85 Million |
| 2015 | -8857.30% | -8085.13% | 0.02x | 47.80x | ILA-15.78 Million |
| 2016 | 0.00% | -10779.52% | 0.01x | 0.00x | ILA-8.80 Million |
| 2017 | 0.00% | -17535.00% | 0.03x | 0.00x | ILA-7.01 Million |
| 2018 | -56.26% | -105.02% | 0.17x | 3.22x | ILA-12.13 Million |
| 2019 | -55.69% | -102.84% | 0.11x | 5.03x | ILA-8.00 Million |
| 2020 | 4.41% | 13.36% | 0.14x | 2.40x | ILA-1.71 Million |
| 2021 | 1.91% | 7.65% | 0.13x | 1.95x | ILA-4.34 Million |
| 2022 | -86.79% | -235.14% | 0.15x | 2.40x | ILA-27.93 Million |
| 2023 | -583.73% | -8969.15% | 0.01x | 5.42x | ILA-25.73 Million |
Industry Comparison
This section compares Erech Finance Cahalacha Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $56,973,000
- Average return on equity (ROE) among peers: -26.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Erech Finance Cahalacha Ltd (EFNC) | ILA4.33 Million | -929.49% | 4.42x | $1.61 Million |
| Allmed Solutions Ltd (ALMD) | $52.31 Million | 5.37% | 0.05x | $8.17 Million |
| Erika Carmel Ltd (BCUR) | $42.67 Million | -76.32% | 0.60x | $4.69 Million |
| Bio-View Ltd (BIOV) | $16.69 Million | 8.64% | 0.79x | $20.36 Million |
| Brainsway Ltd (BWAY) | $10.29 Million | -23.30% | 0.94x | $533.52 Million |
| Epitomee Medical Ltd (EPIT) | $34.80 Million | -16.33% | 0.16x | $26.17 Million |
| Erika Carmel-Tech Ltd (ERKA) | $9.79 Million | -59.80% | 1.98x | $5.65 Million |
| Human Xtensions Ltd (HUMX) | $104.53 Million | -51.30% | 0.15x | $2.12 Million |
| Ilex Medical (ILX) | $109.44 Million | 17.00% | 0.55x | $145.48 Million |
| Pulsenmore Ltd (PULS) | $132.23 Million | -44.29% | 0.36x | $22.89 Million |
About Erech Finance Cahalacha Ltd
Erech Finance Cahalacha Ltd, together with its subsidiaries, provides loans and credit services to small and medium sized enterprises, associations, and private borrowers in Israel. It is also involved in the development of biomed-drugs in the areas of juvenile diabetes and cancer. The company was founded in 1998 and is based in Jerusalem, Israel.